Q-omics provides the consensus-scored SFR1 profile across patient tissues and cancer cell-line models. SFR1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, SFR1 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, SFR1 RNA expression shows 19,874 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UCS, HNSC, and ACC as cancer lineages where SFR1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SFR1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SFR1 survival associations across molecular data types. SFR1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SFR1 RNA expression–survival associations across cancer types. High SFR1 expression shows unfavorable associations in ACC, LIHC and HNSC, but favorable associations in UCS, KIRC and SKCM. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UCS as the clearest survival context for SFR1 RNA expression.
This table summarizes SFR1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for SFR1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SFR1 shows lower tumor expression in KICH and higher tumor expression in HNSC, KIRC, LIHC, STAD and KIRP. The HNSC box plot shows higher SFR1 RNA expression in tumor versus normal tissue (log2 FC = +1.145, t-test p < 0.001).
This table shows molecular features associated with SFR1 in patient tissues and cancer cell lines. In patient samples, SFR1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SFR1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and UPPER_AERODIGESTIVE_TRACT.
